GATAD2A

Across TCGA pan-cancer cohorts, GATAD2A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GATAD2A data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GATAD2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GATAD2A expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

UCEC and STAD are the cancer types where GATAD2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
STAD	DFS	Median	All	0.784	0.335	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

GATAD2A–UCEC (OS)

Open the UCEC breakdown →